Genital Herpes (HSV-2) Treatment Guide

Genital herpes is one of the most common sexually transmitted infections in the United States, yet it remains one of the most misunderstood. The stigma around a diagnosis often overshadows the clinical reality: this is a manageable chronic infection with effective antiviral medications, evidence-based transmission prevention strategies, and a natural tendency toward fewer and milder outbreaks over time.

What I find in practice is that patients newly diagnosed with HSV-2 often fear the worst — constant outbreaks, ruined relationships, dangerous pregnancy complications. Most of those fears don't match the evidence. What matters clinically is understanding your treatment options, knowing when to use them, and having a clear picture of how to protect partners.

This guide covers the full clinical picture: CDC treatment regimens, the difference between suppressive and episodic therapy, how seroprevalence and serology testing work, asymptomatic shedding data, transmission risk reduction, pregnancy management, and where telehealth fits into long-term HSV-2 care.

How Common Is HSV-2? Understanding Seroprevalence

HSV-2 infects approximately 12% of U.S. adults aged 14–49 — roughly 1 in 8 people.^[1] Prevalence is not evenly distributed. Among women aged 14–49, seroprevalence is 15.9%, compared to 8.2% among men in the same age group.^[7] This disparity reflects more efficient male-to-female transmission during unprotected vaginal intercourse, driven partly by differences in mucosal surface area and partly by higher viral shedding rates in men during the first year of infection.

Globally, the WHO estimates over 846 million people aged 15–49 live with genital herpes infections — more than 1 in 5 in that age group worldwide.^[8] These figures include both HSV-1 and HSV-2 genital infections, and the share attributable to HSV-1 has grown substantially due to widespread orogenital sex practices.

One number worth understanding: the majority of people with HSV-2 seropositivity have never been clinically diagnosed. Estimates suggest that 80–90% of HSV-2 seropositive individuals are unaware of their infection because they either have no symptoms or attribute their symptoms to something else. This silent reservoir is the primary driver of ongoing transmission.

HSV-1 vs. HSV-2 Genital Herpes: What's the Difference?

Both HSV-1 and HSV-2 can infect the genital tract, but they behave very differently after the primary episode. HSV-2 reactivates efficiently from sacral nerve ganglia, producing an average of 4–5 symptomatic recurrences per year in the first year of infection and shedding virus on approximately 34% of days in that same period — even when no symptoms are present.^[6] After a decade of infection, shedding drops to roughly 17% of days but never reaches zero.

Genital HSV-1 follows a different trajectory. It is most often acquired through orogenital contact with a partner who has oral HSV-1 (cold sores). After the first episode, recurrences are infrequent — on average fewer than one per year — and viral shedding declines substantially during the first 12 months. Research from the University of Washington found that shedding rates in genital HSV-1 fall sharply in the first year, reaching levels considerably lower than those seen with HSV-2 even a decade post-infection.^[6]

In my practice, patients with genital HSV-1 are often relieved to hear that their infection is less likely to cause frequent recurrences long-term. The flip side is that the transmission prevention data for suppressive therapy applies specifically to HSV-2 discordant couples — if your genital infection is HSV-1, we don't have the same trial evidence to cite.

Diagnosis and Type-Specific Serology: When to Test

Active genital lesions are ideally diagnosed by HSV PCR or viral culture taken directly from the lesion — swab the ulcer base while it's still vesicular or ulcerating for the best yield. PCR is more sensitive than culture and is now the preferred method at most reference labs. A clinical diagnosis based on appearance alone is unreliable; genital ulcer disease has a broad differential including syphilis, chancroid, and traumatic abrasion.

Type-specific serologic testing (HSV-2 IgG) detects antibodies that develop 12–16 weeks after infection. The indications for serology are narrower than many patients expect. The CDC does not recommend routine HSV-2 screening of asymptomatic adults because a positive result in someone with no symptoms creates significant psychological burden without a clear clinical benefit.^[2]

One practical note: the HerpeSelect HSV-2 IgG ELISA, the most commonly used commercial assay, has a false-positive rate that can be clinically meaningful — particularly for low-prevalence populations. When the result is weakly positive (index value 1.1–3.4), the CDC now recommends confirmatory testing with a second assay (such as the Biokit HSV-2 Rapid Test or Western blot) before acting on the result.^[2]

First-Episode Treatment

The first clinical episode of genital herpes tends to be the most severe. Without prior HSV-1 immunity, the primary episode can produce extensive ulceration, systemic flu-like symptoms, inguinal lymphadenopathy, and in some cases urinary retention or aseptic meningitis. Antiviral therapy meaningfully shortens duration and reduces severity — start treatment as soon as possible after onset. The evidence does not support waiting for lab confirmation before initiating antivirals in a patient with a classic clinical presentation.^[1]

If healing is incomplete after 10 days of therapy, extend treatment until lesions are fully resolved. For patients with severe disease — extensive necrotic ulcers, disseminated infection, or HSV meningitis — IV acyclovir (5–10 mg/kg every 8 hours) is indicated until clinical improvement, followed by oral therapy to complete the full course.^[1]

Suppressive Therapy vs. Episodic Therapy

After the first episode, patients have two long-term antiviral strategies: suppressive (daily) therapy or episodic (outbreak-triggered) therapy. The right choice depends on outbreak frequency, relationship context, and patient preference. Neither strategy is wrong — the goal is to match the approach to the individual's clinical situation.

Suppressive Therapy

Suppressive therapy means taking an antiviral every day, regardless of symptoms. The data here are strong: daily valacyclovir reduces HSV-2 recurrence frequency by 70–80%, and many patients on suppression report no symptomatic outbreaks.^[1] Suppression also reduces asymptomatic shedding, which directly lowers transmission risk to partners.

Suppressive therapy should be discussed annually. Recurrence frequency naturally declines over the years as the immune system adapts to the virus, and some patients can eventually transition to episodic therapy — or discontinue antivirals entirely — without significant recurrence burden. The threshold I use to recommend daily suppression: six or more outbreaks per year, or any frequency if the patient is in a discordant relationship and transmission prevention is a priority.^[1]

Episodic Therapy

Episodic therapy means initiating antivirals at the first sign of a recurrence — ideally within 24 hours of symptom onset or prodrome. When started early, episodic therapy shortens outbreak duration by 1–2 days and reduces lesion severity. What it does not do is prevent asymptomatic shedding between episodes or meaningfully reduce transmission risk to partners.^[5]

For episodic therapy to work, patients need to recognize their prodrome — the tingling, itching, or shooting pain that often precedes lesions by 12–24 hours. I routinely provide a prescription to keep on hand so patients can start treatment immediately without waiting for an appointment. The first-day delay caused by waiting for a prescription eliminates most of the clinical benefit of episodic therapy.

Transmission Risk and Prevention

HSV-2 is transmitted primarily through direct skin-to-skin or skin-to-mucosa contact during vaginal, anal, or oral sex. Unlike HIV or gonorrhea, transmission can occur from areas not covered by a condom, which is why condom effectiveness against herpes is lower than against fluid-borne STIs. That said, condoms and antivirals both provide real and additive protection.

Asymptomatic Shedding: The Underappreciated Risk

Most HSV-2 transmission does not occur during an active outbreak. It occurs during periods of asymptomatic shedding — when the virus is present in genital secretions and skin without visible lesions or any symptoms at all. This is why people with no history of outbreaks can transmit the virus to partners, and why avoiding sex only during outbreaks is an incomplete prevention strategy.

Shedding is most frequent in the first 12 months after acquiring HSV-2. The virus is detectable on approximately 34% of days during year one, declining to about 17% of days by year 10 — still a substantial proportion. This biology is the clinical rationale for suppressive therapy even in patients with infrequent symptomatic outbreaks.

Quantifying Risk Reduction

These numbers tell an honest story: antivirals and condoms provide meaningful but incomplete protection. Neither alone eliminates risk. Using both together substantially increases the overall risk reduction. Avoiding sexual contact during outbreaks and prodromal symptoms is a necessary addition to — not a substitute for — pharmacologic and barrier prevention.

Partner Disclosure and Counseling

The CDC recommends that all persons with genital herpes inform current sex partners of their diagnosis and disclose to future partners before beginning a sexual relationship.^[2] This is both an ethical obligation and, in most U.S. states, a legal one when a known risk of transmission exists.

What I tell patients: the disclosure conversation feels harder than it is. Most partners respond better than expected, particularly when you arrive with accurate information about transmission risk and protective strategies. Framing the discussion around management and prevention — rather than the diagnosis as an isolated fact — helps considerably.

Quality of life and relationship impact matter clinically. Stigma around herpes can be more disabling than the infection itself. When patients are anxious, depressed, or experiencing relationship distress from their diagnosis, addressing this directly — including mental health referral when appropriate — is part of good herpes care.

Pregnancy Management

Neonatal herpes is a devastating complication, but it is uncommon when managed appropriately. The risk varies dramatically by timing and immune status: primary infection acquired close to term carries a 30–50% transmission risk to the neonate, while recurrent infection in a woman with established HSV-2 antibodies carries a risk below 1%.^[1] Understanding this distinction drives management decisions.

Suppressive Therapy in Pregnancy

The CDC recommends suppressive antiviral therapy starting at 36 weeks' gestation for all pregnant women with a history of recurrent genital herpes.^[1] This is not optional in patients with known HSV-2 — it is standard of care. A Cochrane review of seven randomized trials found that suppressive therapy from 36 weeks reduced:

• Clinical HSV recurrence at delivery: from 15% (placebo) to 3.8% (treatment), RR 0.28
• Cesarean deliveries for active HSV: from 14% (placebo) to 3.8% (treatment), RR 0.30
• Asymptomatic shedding at delivery: from 6.3% (placebo) to 0.4% (treatment), RR 0.14

Delivery Mode

Cesarean delivery is recommended when active genital lesions or prodromal symptoms (vulvar burning, pain, tingling) are present at the onset of labor.^[1] The presence of active lesions increases vertical transmission risk compared to cesarean delivery (7.7% vaginal delivery vs. 1.2% cesarean). Women with a history of herpes but no active lesions or prodromal symptoms at labor may deliver vaginally.

For women who acquire primary or nonprimary first-episode HSV in the third trimester, the ACOG recommends that cesarean delivery may be offered because of the possibility of prolonged viral shedding — even if lesions have healed. These patients should be managed in consultation with maternal-fetal medicine.

Pregnancy-Specific Additional Considerations

• First-trimester primary infection: Can be associated with spontaneous abortion or fetal abnormalities (chorioretinitis, microcephaly, skin lesions) — early consultation with maternal-fetal medicine is warranted.
• Breastfeeding: Acyclovir and valacyclovir appear safe during breastfeeding. If no lesions are present on the breast, there is no contraindication to nursing.
• Routine serial cultures: Not indicated for women with known recurrent genital herpes. Weekly cervical cultures in the third trimester do not predict shedding status at delivery.
• Routine HSV-2 serology screening of all pregnant women: Not recommended by the CDC. Targeted testing is appropriate in specific clinical scenarios.

HSV-2 in HIV-Positive Patients

HSV-2 is the most common cause of genital ulcer disease in people with HIV, and the two infections interact in clinically meaningful ways. HSV-2 ulcers disrupt mucosal barriers, increasing both HIV acquisition risk and HIV shedding in genital secretions — which in turn raises HIV transmission risk from the co-infected person. The CDC recommends that all persons newly diagnosed with genital herpes be tested for HIV.^[2]

Treatment regimens for HSV in HIV-positive patients use the same agents but at higher doses. For daily suppressive therapy in patients with HIV: acyclovir 400–800 mg two to three times daily, famciclovir 500 mg twice daily, or valacyclovir 500 mg twice daily. Episodic regimens use standard doses but extend treatment to 5–10 days given slower healing in immunocompromised patients. The risk of genital ulcer disease increases in the first 6 months after starting antiretroviral therapy (as immune reconstitution drives HSV reactivation); suppressive therapy during this period reduces that risk.^[2]

One critical caveat: suppressive antiviral therapy for HSV-2 does not reduce the risk of HIV transmission or acquisition, and it does not delay HIV disease progression in patients on effective ART. This misconception occasionally surfaces in clinical discussions and needs to be corrected.

The Role of Telehealth in Herpes Management

Telehealth fits naturally into HSV-2 care because most of what matters happens between outbreaks, not during them. A physician can initiate suppressive or episodic therapy based on history and prior lab results, counsel patients on transmission reduction, order type-specific serology when indicated, and manage ongoing prescriptions — all without an in-person visit.

The initial diagnosis is the one area where telehealth has limits. If you have active lesions that have never been virologically confirmed, you ideally need an in-person swab (PCR or culture from the lesion base) to confirm the diagnosis and determine virus type. Once that is established, all subsequent management — including antiviral prescribing, suppressive therapy titration, pregnancy planning discussions, and partner counseling — can be handled effectively via secure video visit.

For established patients, telehealth removes a meaningful barrier to care. Many people with herpes avoid discussing it with providers because of the stigma associated with in-person STI visits. A private video consultation makes it easier to have direct conversations about disclosure, partner testing, pregnancy planning, and antiviral strategy — conversations that are essential to good clinical outcomes but often don't happen when the barrier to access is high.

When to Seek Urgent or Emergency Care

Most recurrent outbreaks in healthy, immunocompetent adults do not require emergency care. They are self-limiting and respond well to episodic oral antivirals started at symptom onset. The scenarios above represent the exceptions — situations where the infection has moved beyond a localized mucocutaneous process and requires more intensive evaluation or treatment.

Frequently Asked Questions